Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Fundamental Analysis

NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD

0.9001  -0.01 (-1.53%)

After market: 0.9001 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PRLD. PRLD was compared to 561 industry peers in the Biotechnology industry. The financial health of PRLD is average, but there are quite some concerns on its profitability. PRLD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRLD has reported negative net income.
In the past year PRLD has reported a negative cash flow from operations.
In the past 5 years PRLD always reported negative net income.
PRLD had a negative operating cash flow in each of the past 5 years.
PRLD Yearly Net Income VS EBIT VS OCF VS FCFPRLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -72.46%, PRLD is not doing good in the industry: 65.95% of the companies in the same industry are doing better.
With a Return On Equity value of -96.74%, PRLD perfoms like the industry average, outperforming 45.63% of the companies in the same industry.
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROIC N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRLD Yearly ROA, ROE, ROICPRLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRLD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRLD Yearly Profit, Operating, Gross MarginsPRLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

PRLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRLD has been increased compared to 1 year ago.
Compared to 5 years ago, PRLD has more shares outstanding
Compared to 1 year ago, PRLD has a worse debt to assets ratio.
PRLD Yearly Shares OutstandingPRLD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRLD Yearly Total Debt VS Total AssetsPRLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRLD has an Altman-Z score of -5.80. This is a bad value and indicates that PRLD is not financially healthy and even has some risk of bankruptcy.
PRLD has a worse Altman-Z score (-5.80) than 63.10% of its industry peers.
There is no outstanding debt for PRLD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.8
ROIC/WACCN/A
WACC10.05%
PRLD Yearly LT Debt VS Equity VS FCFPRLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

PRLD has a Current Ratio of 5.30. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.30, PRLD perfoms like the industry average, outperforming 57.75% of the companies in the same industry.
PRLD has a Quick Ratio of 5.30. This indicates that PRLD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.30, PRLD perfoms like the industry average, outperforming 58.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.3
Quick Ratio 5.3
PRLD Yearly Current Assets VS Current LiabilitesPRLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.63% over the past year.
EPS 1Y (TTM)9.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.08% on average over the next years. This is quite good.
PRLD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 120.17% yearly.
EPS Next Y-0.25%
EPS Next 2Y13.08%
EPS Next 3Y13.28%
EPS Next 5Y8.08%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.17%

3.3 Evolution

PRLD Yearly Revenue VS EstimatesPRLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2028 2029 2030 2031 2032 100M 200M 300M
PRLD Yearly EPS VS EstimatesPRLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRLD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRLD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRLD Price Earnings VS Forward Price EarningsPRLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRLD Per share dataPRLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as PRLD's earnings are expected to grow with 13.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.08%
EPS Next 3Y13.28%

More info and screens

0

5. Dividend

5.1 Amount

PRLD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (5/22/2025, 8:00:00 PM)

After market: 0.9001 0 (0%)

0.9001

-0.01 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners50.59%
Inst Owner Change-7.49%
Ins Owners9.43%
Ins Owner Change31.23%
Market Cap50.82M
Analysts77.78
Price Target5.1 (466.6%)
Short Float %4.44%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.12%
Min EPS beat(2)10.65%
Max EPS beat(2)19.59%
EPS beat(4)3
Avg EPS beat(4)10.12%
Min EPS beat(4)-4.88%
Max EPS beat(4)19.59%
EPS beat(8)7
Avg EPS beat(8)13.26%
EPS beat(12)11
Avg EPS beat(12)10.59%
EPS beat(16)11
Avg EPS beat(16)6.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.36%
EPS NQ rev (3m)-5.64%
EPS NY rev (1m)-2.45%
EPS NY rev (3m)-10.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.26
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-1.69
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.12
BVpS2.33
TBVpS2.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.46%
ROE -96.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.23%
ROA(5y)-46.15%
ROE(3y)-69.07%
ROE(5y)-54.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.12%
Cap/Sales 10.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.3
Quick Ratio 5.3
Altman-Z -5.8
F-Score4
WACC10.05%
ROIC/WACCN/A
Cap/Depr(3y)190.81%
Cap/Depr(5y)187.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-0.25%
EPS Next 2Y13.08%
EPS Next 3Y13.28%
EPS Next 5Y8.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y120.17%
EBIT growth 1Y-5.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.9%
OCF growth 3YN/A
OCF growth 5YN/A